Skip to main content
. Author manuscript; available in PMC: 2022 Aug 25.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2021 Jul 2;21(11):e886–e894. doi: 10.1016/j.clml.2021.06.021

Figure 1. Study design of the CHRONOS-4 Phase III study—safety run-in.

Figure 1

CHOP treatment includes cyclophosphamide 750 mg/m2 i.v., doxorubicin 50 mg/m2 i.v., and vincristine 1.4 mg/m2 i.v. (maximum dose 2.0 mg) on day 2 of a 21-day cycle, and prednisone 100 mg tablets on days 2 to 6 of a 21-day cycle. Abbreviations: B = bendamustine; CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; i.v. = intravenous; R = rituximab; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RP3D = recommended Phase III dose.